Sanofi SA
SAN: XPAR (FRA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€663.00 | Wlzh | Sxwmbpxr |
Sanofi: Vaccine Research and Development Update Reinforces Steady Long-Term Growth Outlook
Sanofi’s vaccine research and development update provided details on core franchises and new vaccines but didn’t impact our fair value estimate. The encouraging pipeline developments reaffirm our conviction in the firm’s wide moat. We believe Sanofi will likely meet its vaccine sales expectation of over EUR 10 billion by 2030, up from close to EUR 5 billion in 2018.